FDC [FDC] vs Procter & Gamble [PGHL] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: FDC Ltd. wins in 9 metrics, Procter & Gamble Health Ltd. wins in 11 metrics, with 0 ties. Procter & Gamble Health Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | FDC Ltd. | Procter & Gamble Health Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 26.95 | 36.48 | FDC Ltd. |
| Price-to-Book Ratio | 2.39 | 13.94 | FDC Ltd. |
| Debt-to-Equity Ratio | 0.85 | 1.00 | FDC Ltd. |
| PEG Ratio | -1.14 | -2.49 | FDC Ltd. |
| EV/EBITDA | 19.98 | 21.21 | FDC Ltd. |
| Profit Margin (TTM) | 10.43% | 21.76% | Procter & Gamble Health Ltd. |
| Operating Margin (TTM) | 8.07% | 27.97% | Procter & Gamble Health Ltd. |
| EBITDA Margin (TTM) | 8.07% | 27.97% | Procter & Gamble Health Ltd. |
| Return on Equity | 11.70% | 37.34% | Procter & Gamble Health Ltd. |
| Return on Assets (TTM) | 9.83% | 25.30% | Procter & Gamble Health Ltd. |
| Free Cash Flow (TTM) | $2.21B | $2.07B | FDC Ltd. |
| Dividend Yield | 1.29% | 5.20% | Procter & Gamble Health Ltd. |
| 1-Year Return | -18.49% | 7.82% | Procter & Gamble Health Ltd. |
| Price-to-Sales Ratio (TTM) | 2.81 | 6.41 | FDC Ltd. |
| Enterprise Value | $55.13B | $83.62B | Procter & Gamble Health Ltd. |
| EV/Revenue Ratio | 2.65 | 6.20 | FDC Ltd. |
| Gross Profit Margin (TTM) | 67.39% | 70.63% | Procter & Gamble Health Ltd. |
| Revenue per Share (TTM) | $128 | $812 | Procter & Gamble Health Ltd. |
| Earnings per Share (Diluted) | $13.32 | $142.69 | Procter & Gamble Health Ltd. |
| Beta (Stock Volatility) | 0.05 | 0.09 | FDC Ltd. |
FDC Ltd. vs Procter & Gamble Health Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| FDC Ltd. | -0.79% | 0.93% | 5.09% | 12.73% | -8.56% | -8.13% |
| Procter & Gamble Health Ltd. | -0.96% | 0.44% | 17.48% | 27.00% | 9.90% | 8.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| FDC Ltd. | -18.49% | 25.52% | 12.27% | 115.89% | 298.61% | 910.03% |
| Procter & Gamble Health Ltd. | 7.82% | 23.28% | 7.21% | 805.06% | 944.18% | 1,263.48% |
Performance & Financial Health Analysis: FDC Ltd. vs Procter & Gamble Health Ltd.
| Metric | FDC | PGHL |
|---|---|---|
| Market Information | ||
| Market Cap | ₹60.56B | ₹86.41B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 73,542 | 29,937 |
| 90 Day Avg. Volume | 110,646 | 19,044 |
| Last Close | ₹384.80 | ₹6,226.50 |
| 52 Week Range | ₹312.95 - ₹527.80 | ₹4,707.00 - ₹6,739.00 |
| % from 52W High | -27.09% | -7.60% |
| All-Time High | ₹658.85 (Sep 09, 2024) | ₹7,500.00 (Feb 08, 2021) |
| % from All-Time High | -41.60% | -16.98% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | 0.21% |
| Quarterly Earnings Growth | -0.24% | -0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.22% |
| Operating Margin (TTM) | 0.08% | 0.28% |
| Return on Equity (TTM) | 0.12% | 0.37% |
| Debt to Equity (MRQ) | 0.85 | 1.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹149.97 | ₹373.35 |
| Cash per Share (MRQ) | ₹26.14 | ₹172.39 |
| Operating Cash Flow (TTM) | ₹3.54B | ₹3.20B |
| Levered Free Cash Flow (TTM) | ₹2.67B | ₹2.01B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.29% | 5.20% |
| Last 12-Month Dividend | ₹5.00 | ₹285.00 |
Valuation & Enterprise Metrics Analysis: FDC Ltd. vs Procter & Gamble Health Ltd.
| Metric | FDC (Apr 24, 2026) | PGHL (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 26.95 | 36.48 |
| Forward P/E | 15.41 | 27.46 |
| PEG Ratio | -1.14 | -2.49 |
| Price to Sales (TTM) | 2.81 | 6.41 |
| Price to Book (MRQ) | 2.39 | 13.94 |
| Market Capitalization | ||
| Market Capitalization | ₹60.56B | ₹86.41B |
| Enterprise Value | ₹55.13B | ₹83.62B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.65 | 6.20 |
| Enterprise to EBITDA | 19.98 | 21.21 |
| Risk & Other Metrics | ||
| Beta | 0.05 | 0.09 |
| Book Value per Share (MRQ) | ₹149.97 | ₹373.35 |
Financial Statements Comparison: FDC Ltd. vs Procter & Gamble Health Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | FDC (2025) | PGHL (2024) |
|---|---|---|
| Revenue/Sales | 21.03B | 11.29B |
| Cost of Goods Sold | 7.59B | 3.59B |
| COGS % of Revenue | 36.1% | 31.8% |
| Gross Profit | 13.43B | 7.70B |
| Gross Margin | 63.9% | 68.2% |
| Research & Development | 81.96M | 38.60M |
| Operating Income (EBIT) | 2.71B | 2.79B |
| Operating Margin | 12.9% | 24.7% |
| EBITDA | 3.80B | 3.22B |
| EBITDA Margin | 18.1% | 28.5% |
| Pre-Tax Income | 3.57B | 2.73B |
| Pre-Tax Income % of Revenue | 17.0% | 24.2% |
| Income Tax | 904.30M | 723.40M |
| Income Tax % of Revenue | 4.3% | 6.4% |
| Net Income (Profit) | 2.67B | 2.01B |
| Profit Margin | 12.7% | 17.8% |
Balance Sheet & Liquidity Metrics
| Metric | FDC (2025) | PGHL (2024) |
|---|---|---|
| Cash & Equivalents | 514.72M | 2.39B |
| Total Current Assets | 10.89B | 5.24B |
| Total Current Assets % of Revenue | 51.8% | 46.4% |
| Total Current Liabilities | 3.62B | 2.19B |
| Total Current Liabilities % of Revenue | 17.2% | 19.4% |
| Long-Term Debt | 121.17M | 68.80M |
| Long-Term Debt % of Revenue | 0.6% | 0.6% |
| Total Shareholders Equity | 22.81B | 5.38B |
| Retained Earnings | 19.42B | 1.58B |
| Retained Earnings % of Revenue | 92.4% | 14.0% |
| Property, Plant & Equipment | 204.53M | 1.26B |
Cash Flow Statement Comparison
| Metric | FDC (2025) | PGHL (2024) |
|---|---|---|
| Operating Cash Flow | 3.54B | 3.20B |
| Operating Cash Flow % of Revenue | 16.8% | 28.4% |
| Capital Expenditures | -909.37M | -217.30M |
| Free Cash Flow | 2.21B | 2.07B |
| FCF Margin | 10.5% | 18.3% |
| Debt Repayment | -321,000 | N/A |
| Common Stock Repurchase | 0 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | FDC | PGHL |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 162.81M | 16.60M |
| Float Shares | 48.87M | 7.93M |
| % Held by Insiders | 69.95% | 52.20% |
| % Held by Institutions | 7.50% | 15.99% |
| % Held by Public | 22.55% | 31.81% |
Dividend Analysis & Yield Comparison: FDC Ltd. vs Procter & Gamble Health Ltd.
| Metric | FDC | PGHL |
|---|---|---|
| Last 12-Month Dividend | ₹5.00 | ₹285.00 |
| Last 12-Month Dividend Yield | 1.29% | 5.20% |
| 3-Year Avg Annual Dividend | ₹3.33 | ₹213.33 |
| 3-Year Avg Dividend Yield | 1.14% | 1.75% |
| 3-Year Total Dividends | ₹10.00 | ₹640.00 |
| Ex-Dividend Date | Feb 11, 2026 | Feb 12, 2026 |